Time	Title	Speaker
9-10	Arrival and Registration with coffee and pastries	
Opening Keynote		
10-10.30	Reducing the Risk of Mitochondrially Active Compounds in Medicines Development	Dr Jon Lyon – Director of Preclinical Toxicity and Mitochondrial Network Lead, GSK
Morning Session		
1030-11	Assessing Cardiac Ion Channel Activity in the Drug Discovery Cascade	Dr Mike Morton, ApconiX
11-1130	The role of Target Safety Assessments (TSAs) in derisking drug projects	Dr James Sidaway, ApconiX
1130-12	Making formulation part of drug design: case studies	Dr Linette Ruston, Director, ADME and Modelling Sciences, SEDA Pharmaceuticals
12-13	Lunch Break	
Afternoon Session		
13-1330	DMPK in drug design (TBC)	Dr Kevin Beaumont, Senior Director, DMPK, AstraZeneca
13-30-14	Developing an ion channel seizure panel	Dr Kim Rockley, ApconiX
14-1430	Designing out secondary pharmacology hits	Dr Mark Anderton, Senior Principal Scientist, MSD
1430-15	Coffee/Tea	
15-1530	State-of-the-art cellular models in de-risking drug design	Dr Colin Brown, Chief Innovation Officer, Newcells Biotech
1530-1600	Making safety part of drug design – a regulatory perspective	Dr David Jones, ApconiX
1600	Panel discussion (TBC)	
1630	Close	